Intergen and Immunosis Announce Partnership to Advance RNA-Based Diagnosis for Patients with Immune Dysregulation.
This partnership addresses a critical unmet need by combining Immunosis’ proprietary RNAinsights platform- capable of detecting immune dysfunction at a functional, molecular level- with Intergen Genetics’ established clinical laboratory and R&D infrastructure, and regional delivery capabilities. Together, the companies are creating a scalable pathway to bring next-generation immune diagnostics into routine clinical practice across the Middle East and North Africa (MENA).
The first product to be commercialised under the partnership, PrimDx, has been developed by Immunosis for patients with Primary Immunodeficiency (PID). Built on the RNAinsights platform, PrimDx uses advanced transcriptomic analysis to identify patterns of immune dysregulation that may not be detectable through DNA testing alone. In clinical studies involving 180 participants, PrimDx demonstrated an overall diagnostic accuracy of 95%, highlighting its potential to improve diagnostic confidence and reduce the need for prolonged diagnostic journeys.
Under the agreement, Intergen Genetics will lead the commercialisation of PrimDx across the MENA region, with the first phase of rollout expected to begin in 2026. The partnership is designed to expand access to cutting-edge genomic and immune-based diagnostics, supporting clinicians in making faster, more informed decisions and improving outcomes for patients with rare and complex immune conditions.
“Patients with primary immunodeficiencies often experience long and challenging diagnostic journeys, sometimes lasting several years. By integrating RNA-based insights into clinical practice, we have the opportunity to transform how these conditions are identified and managed,” said Professor Dr Ceylaner. “This partnership strengthens our ability to deliver comprehensive, clinically actionable diagnostics to patients across our region.”
Dr. Simon Green, CEO of Immunosis, added: “Our RNAinsights platform was designed to uncover functional immune abnormalities that traditional approaches can miss. Partnering with Intergen Genetics allows us to translate this technology into real-world clinical impact at scale, bringing faster, more precise answers to patients and their physicians in a region where access to advanced diagnostics is rapidly evolving.”
In Türkiye, the incidence of Primary Immunodeficiency is estimated at approximately 1 in 10,000 individuals, with diagnosis often delayed by several years due to recurrent infections and limitations in existing diagnostic approaches. Earlier and more accurate detection has the potential to significantly improve patient outcomes and reduce healthcare burden.
.
About Immunosis
Immunosis is an Australian-based biotechnology company specialising in advanced immune profiling and precision diagnostics. Its proprietary RNAinsights platform utilises transcriptomic data and AI-driven prediction algorithms to decode immune system function, with its lead product PrimDx focused on improving the diagnosis and management of Primary Immunodeficiency.